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Zinc (Zn) has the potential of regulating the action of thiazolidinedione (TZD), an anti-diabetic drug. Since some 
diabetic patients cannot achieve optimal glycemic control when receiving TZD, we investigated if Zn deficiency 
affects TZD’s efficacy in glucose metabolism. Diabetic mice were fed diets containing 3 or 30 mg/kg Zn for 6 weeks. 
Thereafter, all mice were oral gavaged with 2,4-thiazolidinedione. Our results showed that blood glucose values at 
fasting and during the glucose tolerance test were significantly higher in low-Zn mice than those of adequate-Zn 
mice. Thus, low Zn intake may attenuate TZD’s efficacy on reducing diabetic hyperglycemia.
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Type 2 diabetes mellitus has become a serious public health problem worldwide (13). The 
pivotal mediator for the various manifestations of diabetic complications, including 
cardiovascular disorders, may be attributed to the oxidative stress derived from factors like 
hyperglycemia and inflammatory response (2). Zinc (Zn) closely participates in the 
metabolism of carbohydrate, protein and fat (7). Its deficiency causes a variety of physiological 
defects, such as growth retardation, immune depression, and acrodermatitis, etc (10). 
However, reduced Zn intake has become prevalent in many countries (18). Zn also plays an 
important role in mediating the production and signaling of insulin (17). Diabetic subjects 
usually have hypozincemia and hyperzincuria, and correction of the Zn status has been 
proposed as a therapeutic option for diabetic patients (6). 
Peroxisome proliferators-activated receptor (PPAR) can act as transcription factor to 
regulate the activity of various genes, such as nuclear factor kappa B (NF-κB) (12). Although 
the full pharmacological mechanisms remain unclear, PPAR agonists, of note the 
thiazolidinediones (TZDs) have been widely administered as an insulin sensitizer to type 2 
diabetic patients (12). However, these TZDs have been withdrawn or under restriction due to 
Corresponding author: Prof. Dr. Ming-Der Chen
General Education Center, Overseas Chinese University
No. 100 Chiao-Kwang Road, Taichung 40721, Taiwan
Phone: +886-4-27016855 ext. 2182; E-mails: mdchen@ocu.edu.tw; mdchen1104@gmail.com 
460
Acta Physiologica Hungarica 102, 2015
Song Y-M et al.
the increased risk of hepatitis (troglitazone), bladder cancer (pioglitazone), and cardiovascular 
events (rosiglitazone), respectively. Upon re-evaluation of new data in 2013, the US-FDA 
lifted the restriction on prescribing rosiglitazone. 
Zn is known as an essential constituent of PPARs (4). Furthermore, Zn deficiency 
reduces anti-inflammatory activity of TZD, and the decrease is reversed after Zn repletion 
(8, 11). In clinical practice, some diabetic patients cannot achieve optimal glycemic control 
when given TZD therapy (5). The failure of TZD therapy may be associated with the intrinsic 
difference in adiposity among patients, which is complicated by TZD’s effect on adipocyte 
differentiation and altered production of adipokines (16). It also seems reasonable to suppose 
that some patients with TZD inefficacy may have Zn deficiency. The purpose of this 
preliminary study was to examine if low dietary Zn intake attenuates the efficacy of 
2,4-thiazolidinedione on reducing diabetic hyperglycemia.
Materials and Methods
Weanling male db/db mice were obtained from the Jackson Laboratory (Bar Harbor, ME, 
USA). The db/db mouse, characterized by hyperglycemia, hyperinsulinemia, and leptin-
resistant obesity, closely resembles the metabolic profile of type 2 diabetes mellitus. Mice at 
5 weeks of age were assigned to diet with low (3 mg/kg) or adequate (30 mg/kg) Zn. Each 
group contained 7 mice. Diets were prepared as in a previous study (15). Throughout the 
study, all mice had free access to diet and deionized water. 
At the end of a 6-week Zn treatment period, fasting blood samples were obtained by tail 
cutting from all mice. Circulating concentrations of glucose, insulin, and Zn were 
measured. Thereafter, without changing their original Zn treatment, all mice were given 
2,4-thiazolidinedione (30 mg/kg BW/d, Sigma, St. Louis, MO, USA) for a further week by 
oral gavage. After completion of 2,4-thiazolidinedione administration, mice were fasted for 
6 h and subjected to the oral glucose tolerance test (1 g glucose/kg BW) by following the 
method described previously (1). A protocol for animal care procedure was approved by the 
OCU Research Management and Review Committee (Ocit-RD-99A-061).
Body fat content was determined by a body composition analyzer (EM-SCAN Inc., 
Springfield, IL, USA). Glucose level was measured with a blood glucose meter (Lifescan 
Surestep, Johnson & Johnson, Milpitas, CA, USA). Insulin measurement (Crystal Chem 
Inc., Chicago, IL, USA) was performed by enzyme-linked immunoabsorbent assay. Zn 
concentration was determined by an atomic absorption spectrophotometer (Instrumenation 
Lab., Wilmington, MA, USA). 
All measurements were done on all 7 mice in each group, and the data were presented 
as the mean ± SD. Statistical analyses of the results were conducted by ANOVA and unpaired 
Student’s t-test with a commercial package, KaleidaGraph 3.6 for Macintosh. The difference 
was considered to be significant when P value was < 0.05.
Results
Our data showed that the mice fed low-Zn diet (LZ) had significantly decreased body weight 
and body fat but similar diet consumption when compared with mice with adequate Zn intake 
(AZ). LZ mice also had significantly higher glucose (36%) and lower insulin (47%) compared 
to that of AZ mice (Table I). 
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Table I. Effects of dietary zinc treatment for 6 weeks on food intake, body weight,  
body fat, and determined plasma variables in db/db mice
AZ group (n = 7) LZ group (n = 7) P value
Food intake (g) 5.8 ± 1.0 4.9 ± 1.3 0.173
Body weight (g) 33.5 ± 2.4 28.3 ± 3.6 0.010
Body fat (%) 34.2 ± 4.7 25.6 ± 3.5 0.003
Glucose (mM) 18.2 ± 3.0 24.7 ± 5.2 0.019
Insulin (pM) 6294 ± 1006 3316 ± 785 0.001
Zinc (μM) 13.3 ± 2.7 12.0 ± 5.1 0.546
Mean ± SD. AZ group: adequate zinc diet (30 mg/kg); LZ group: low zinc diet (3 mg/kg)
After completion of 2,4-thiazolidinedione administration, fasting blood glucose values 
of both groups were decreased, though to a less extent in LZ mice, than those at pre-
administration period (AZ mice: from 18.2 ± 3.0 to 12.9 ± 2.2 mM, P = 0.004; LZ mice: from 
24.7 ± 5.2 to 20.0 ± 4.6 mM, P = 0.100). LZ mice also exhibited impaired glucose tolerance, 
as manifested by higher blood glucose levels at 30 and 60 min after the glucose load (Fig. 1), 
resulting in a 39% increase in the AUC (area under curve in glucose challenge test) for 
glucose (1532 ± 408 vs 1100 ± 147 mM, P = 0.030).
Fig. 1. Effects of 2, 4-thiazolidinedione treatment (30 mg/kg/d) for a week on blood glucose levels after the 
administration of the glucose load (1 g glucose/kg, ip) in db/db mice fed diets with 30 mg/kg Zn (AZ) or 3 mg/kg 
Zn (LZ). Data are expressed as mean ± SD. There is significant difference (*: P < 0.05, **: P < 0.01) between 
groups at the same sampling time
Discussion
Consistent with previous studies (6, 15), low Zn intake markedly increased glucose and 
decreased insulin in db/db mice. Since Zn mediates the production of insulin (17), higher 
glucose and lower insulin observed in db/db mice fed low Zn diet might be attributed to Zn-
deficiency-induced reduction in insulin availability. Moreover, Zn deficiency worsened 
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peripheral glucose utilization and lipogenesis which result in the reduction in body weight 
and body fat accumulation (15). However, whether Zn-deficiency-induced exacerbation of 
diabetic hyperglycemia is primarily due to the change in insulin synthesis, or its peripheral 
clearance, or other causes such as tissue Zn maldistribution (9), remains to be elucidated. 
Extreme Zn deficiency causes anorexia (18). However, according to our experience and 
previous studies (6, 14, 15), low Zn, but not totally depleted, has no significant influence on 
the amount of food intake. A pair-fed group of mice was thus not included in this study. 
During a 7-week period of low Zn treatment, our mice exhibited no obvious disorders, such 
as skin lesions or growth retardation (assessed by tail length, data not shown). Consistent 
with previous studies (14, 15) using various Zn doses (0.4 or 5 mg/kg), serum Zn levels did 
not markedly alter by low Zn intake. Our data indicated that a short-term period (7 weeks) of 
low dietary Zn treatment (3 mg/kg) did not cause severe Zn deficiency. Circulating Zn status 
might be able to maintain homeostasis by mobilizing Zn from other peripheral tissues like 
liver during dietary Zn depletion. Previous studies indeed have shown that Zn concentrations 
in liver (14) and bone (15) are decreased in mice when fed the Zn-deficient diet. In this study, 
LZ group also had lower Zn levels in pancreas and epididymal fat, though non-significant, 
than that of AZ group (pancreas: 23.2 ± 9.0 vs 29.5 ± 7.5; fat: 10.7 ± 2.3 vs 13.1 ± 2.4 μg/g 
tissue). 
Chronic inflammation is crucial for the pathogenesis of obesity-related metabolic 
dysfunctions, including type 2 diabetes mellitus (2). Excess fat mass causes an elevation in 
circulating proinflammatory markers, like IL-6, TNFα, and C-reactive protein (3). PPAR is 
linked to the negative regulation of macrophage activation through inhibition of NF-κB and 
the induced expression of factors like adiponectin (16). On the other hand, subjects with Zn 
deficiency are known to catch infections more readily (18). Zn not only participates in 
humoral immunity by regulating B-cell apoptosis and B-cell response to vaccination, but also 
affects T helper cells and the cytokines secreted by them, and the activation of natural killer 
cells (10). Hennig et al. firstly indicated that Zn can modulate PPARs signaling and associated 
regulation of inflammation reaction (8, 11). Zn deficiency also interacts with rosiglitazone to 
induce proatherogenic lipid profiles in low-density lipoprotein receptor (LDL-R) KO mice 
(LDL-R–/–) (14). Although we did not measure circulating cytokines in our mice, the data 
described above suggest that Zn nutritional state should modulate the pathogenesis of 
inflammatory diseases. Interestingly, rosiglitazone has no influence on plasma glucose in 
LDL-R–/– mice regardless of the amount of zinc intake (14). However, we did find that 
2,4-thiazolidinedione effectively reduced hyperglycemia in db/db mice, and the efficacy was 
less in mice with low Zn intake. The discrepancy in glycemic response might be due to the 
intrinsic feature of experimental mice (db/db: hyperglycemia or LDL-R–/–: normoglycemia), 
the dose of Zn selected to induce Zn deficiency (3 or 0.4 mg/kg), and the type of TZD 
(2,4-thiazolidinedione or rosiglitazone) administered. Nevertheless, these data indicate that 
there is an interaction existing between dietary Zn intake and the activity of PPAR agonists. 
In summary, our data confirm that low dietary Zn intake exacerbates hyperglycemia of 
the db/db mice. Furthermore, low Zn intake, even at no apparent Zn deficient status, could 
attenuate the efficacy of TZD on reducing diabetic hyperglycemia. Therefore, adequate 
dietary Zn intake might be critical for diabetic patients when receiving TZD therapy.
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